Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast imaging agent for use in patients with suboptimal echocardiograms; TechneLite, a self-contained system or generator of technetium used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function, and imaging of cerebral blood flow. The company also offers injectable technetium-labeled imaging agents, including Cardiolite, used in myocardial perfusion imaging (MPI) procedures; and Neurolite, which is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect coronary artery disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors, including lymphoma; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with various kinds of cancer. Further, the company offers Gludef an injectable fluorine-18-radiolabeled imaging agent used to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Ablavar, an injectable gadolinium-based contrast agent, which is used to diagnose narrowing or blockage of iliac arteries in known or suspected peripheral vascular disease. Additionally, it is developing flurpiridaz F 18 and 18F LMI 1195 that are under clinical development; and LMI 1174, which is in pre-clinical development. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies, as well as wholesalers. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.